down arrow

biote Corp.

  • Market Cap: Micro Cap
  • Industry: Hospital
  • ISIN: US0906831039
USD
2.78
0.03 (1.09%)

Dec 19

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

2.672.80

52 Week

2.316.36
Valuation
Technical
Day's Volume

CASH

205.21 k

Shareholding (Jun 2025)

FII

3.16%

Held by 27 FIIs

DII

78.92%

Held by 21 DIIs

Promoter

0.00%

How big is biote Corp.?

22-Jun-2025

As of Jun 18, biote Corp. has a market capitalization of 156.74 million, with net sales of 199.37 million and a net profit of 21.51 million over the latest four quarters. The balance sheet shows shareholder's funds of -105.93 million and total assets of 122.37 million.

As of Jun 18, biote Corp. has a market capitalization of 156.74 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the company reported net sales of 199.37 million for the latest four quarters, along with a net profit of 21.51 million during the same period.<BR><BR>As of Dec 24, the balance sheet shows shareholder's funds of -105.93 million and total assets amounting to 122.37 million.

Read More

What does biote Corp. do?

22-Jun-2025

biote Corp. is a micro-cap company in the hospital industry, reporting net sales of $49 million and a net profit of $16 million as of March 2025. Key financial metrics include a P/E ratio of 5.00 and a market cap of $156.74 million.

Overview:<BR>biote Corp. operates in the hospital industry and is classified as a micro-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 49 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 16 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 156.74 Million, Category: Micro Cap<BR><BR>Key Metrics:<BR>P/E: 5.00 <BR>Dividend Yield: 0.00% <BR>Debt Equity: -1.50 <BR>Return on Equity: -33.29% <BR>Price to Book: -1.74 <BR><BR>Contact Details:<BR>Registrar Address: Not available.

Read More

Is biote Corp. overvalued or undervalued?

25-Jun-2025

As of June 22, 2022, Biote Corp. is considered a risky investment but appears undervalued with a low P/E ratio of 5.23, suggesting potential growth despite recent struggles and a year-to-date return of -35.11%.

As of 22 June 2022, the valuation grade for Biote Corp. has moved from does not qualify to risky, indicating a shift in perception towards the company's financial health. The company appears to be undervalued, particularly when considering its low P/E ratio of 5.23 compared to peers, alongside an EV to EBITDA ratio of 6.63 and a PEG ratio of 0.43, which suggests potential for growth relative to its price.<BR><BR>In comparison to its peers, Biote Corp. has a significantly lower P/E ratio than National HealthCare Corp., which stands at 15.83, and a comparable EV to EBITDA ratio to Brookdale Senior Living, Inc. at 3.19. Despite the company's recent struggles, including a year-to-date return of -35.11% compared to the S&P 500's 2.44%, the underlying metrics indicate that Biote Corp. may present a buying opportunity for investors seeking value in the biotech sector.

Read More

Is biote Corp. technically bullish or bearish?

20-Sep-2025

As of August 7, 2025, biote Corp. is in a bearish trend, indicated by negative signals from MACD, moving averages, and Bollinger Bands, with a year-to-date return of -45.47% compared to the S&P 500's 12.22%.

As of 7 August 2025, the technical trend for biote Corp. has changed from mildly bearish to bearish. The current stance is bearish with a strong indication from the MACD, which is bearish on both weekly and monthly time frames. The moving averages are also bearish on a daily basis, and the Bollinger Bands reflect a bearish trend on both weekly and monthly periods. Additionally, the KST is bearish for both time frames, while the Dow Theory shows no trend. <BR><BR>In terms of performance, biote Corp. has underperformed the S&P 500 significantly, with a year-to-date return of -45.47% compared to the S&P 500's 12.22%, and a one-year return of -42.69% versus the S&P 500's 17.14%.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

With a Negative Book Value, the company has a Weak Long Term Fundamental Strength

  • Poor long term growth as Operating profit has grown by an annual rate 115.19% of over the last 5 years
  • Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of 1.54
2

The company has declared negative results in Mar'2025 after 2 consecutive positive quarters

3

Risky - Negative Book Value

4

Below par performance in long term as well as near term

stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Hospital

stock-summary
Market cap

USD 176 Million (Micro Cap)

stock-summary
P/E

5.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-1.54

stock-summary
Return on Equity

-37.27%

stock-summary
Price to Book

-2.07

Revenue and Profits:
Net Sales:
49 Million
(Quarterly Results - Jun 2025)
Net Profit:
4 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-12.03%
0%
-12.03%
6 Months
-30.33%
0%
-30.33%
1 Year
-51.74%
0%
-51.74%
2 Years
-44.73%
0%
-44.73%
3 Years
-29.8%
0%
-29.8%
4 Years
-71.66%
0%
-71.66%
5 Years
0%
0%
0.0%

biote Corp. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Biote Corp. Stock Plummets to New 52-Week Low of $2.65

Biote Corp. Stock Plummets to New 52-Week Low of $2.65

biote Corp., a microcap in the hospital sector, has hit a new 52-week low, reflecting a significant decline in its stock performance over the past year. The company faces financial challenges, including negative book value and a concerning debt-to-equity ratio, alongside a notable drop in net profit and inventory turnover.

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
106.75%
EBIT Growth (5y)
115.19%
EBIT to Interest (avg)
1.54
Debt to EBITDA (avg)
1.96
Net Debt to Equity (avg)
-1.50
Sales to Capital Employed (avg)
-0.53
Tax Ratio
1.34%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
60.28%
ROCE (avg)
44.86%
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
5
Industry P/E
Price to Book Value
-1.70
EV to EBIT
7.14
EV to EBITDA
6.54
EV to Capital Employed
6.41
EV to Sales
1.44
PEG Ratio
0.42
Dividend Yield
NA
ROCE (Latest)
89.72%
ROE (Latest)
Negative BV
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
No Trend
No Trend
OBV
No Trend
Mildly Bearish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Jun 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 35 Schemes (17.89%)

Foreign Institutions

Held by 27 Foreign Institutions (3.16%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is -0.20% vs -1.61% in Mar 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is -75.32% vs 351.43% in Mar 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "48.90",
          "val2": "49.00",
          "chgp": "-0.20%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "12.50",
          "val2": "11.30",
          "chgp": "10.62%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "2.90",
          "val2": "2.90",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-2.60",
          "val2": "9.90",
          "chgp": "-126.26%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "3.90",
          "val2": "15.80",
          "chgp": "-75.32%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "236.70%",
          "val2": "213.30%",
          "chgp": "2.34%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 6.36% vs 12.36% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 100.00% vs -315.38% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "197.20",
          "val2": "185.40",
          "chgp": "6.36%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "45.00",
          "val2": "46.20",
          "chgp": "-2.60%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "11.00",
          "val2": "6.40",
          "chgp": "71.88%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-29.40",
          "val2": "-37.00",
          "chgp": "20.54%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "0.00",
          "val2": "-2.80",
          "chgp": "100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "209.90%",
          "val2": "233.20%",
          "chgp": "-2.33%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQstock-summary
Jun'25
Mar'25
Change(%)
Net Sales
48.90
49.00
-0.20%
Operating Profit (PBDIT) excl Other Income
12.50
11.30
10.62%
Interest
2.90
2.90
Exceptional Items
-2.60
9.90
-126.26%
Consolidate Net Profit
3.90
15.80
-75.32%
Operating Profit Margin (Excl OI)
236.70%
213.30%
2.34%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

QoQ Growth in quarter ended Jun 2025 is -0.20% vs -1.61% in Mar 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is -75.32% vs 351.43% in Mar 2025

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
197.20
185.40
6.36%
Operating Profit (PBDIT) excl Other Income
45.00
46.20
-2.60%
Interest
11.00
6.40
71.88%
Exceptional Items
-29.40
-37.00
20.54%
Consolidate Net Profit
0.00
-2.80
100.00%
Operating Profit Margin (Excl OI)
209.90%
233.20%
-2.33%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is 6.36% vs 12.36% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 100.00% vs -315.38% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About biote Corp. stock-summary
stock-summary
biote Corp.
Hospital
No Details Available.
Company Coordinates stock-summary
Icon
No Company Details Available
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."